1. Inicio
  2. Publicaciones
  3. Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement

Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Malard F.
  • Peric Z.
  • Ruggeri A.
  • Gedde-Dahl T.
  • Bazarbachi A.
  • Ciceri F.
  • Mehra V.
  • Blaise D.
  • Kinsella F.
  • Schoemans H.
  • Bonifazi F.
  • de Witte M.
  • Morsink L.
  • Duarte R.
  • Spyridonidis A.
  • Tavori G.
  • Greinix H.T.
  • Nagler A.
  • Holler E.
  • Zeiser R.
  • Mohty M.

Grupos

Abstract

Chronic graft-versus-host disease (cGVHD) remains the leading cause of late morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation, despite major advances in transplant techniques and supportive care. This European position statement provides a comprehensive and forward-looking synthesis of the evolving biology, epidemiology, diagnosis, and management of cGVHD, while highlighting critical unmet needs that impede progress. cGVHD arises from a complex interplay of immune dysregulation, aberrant tissue repair, and progressive fibrosis, resulting in a heterogeneous clinical spectrum that profoundly impairs quality of life and functional status. Although recent therapeutic innovations—including JAK inhibition, ROCK2 inhibition, and CSF-1R–directed therapies—have expanded options beyond corticosteroids, treatment responses remain variable, and optimal sequencing, biomarkers of activity, and organ-specific strategies are lacking. Persistent challenges in diagnosis, staging reproducibility, integration of patient-reported outcomes, and harmonized clinical trial endpoints further limit clinical and regulatory advancement. The substantial pharmaco-economic burden of cGVHD underscores the urgency of developing more effective, durable, and accessible interventions. This review outlines a collaborative roadmap centered on biomarker-driven precision medicine, harmonized assessment tools, integrated supportive care, and international research networks, aiming to transform cGVHD from a debilitating complication into a predictable, preventable, and ultimately curable condition. © The Author(s), under exclusive licence to Springer Nature Limited 2026.

Datos de la publicación

ISSN/ISSNe:
0268-3369, 1476-5365

BONE MARROW TRANSPLANTATION  SPRINGERNATURE

Tipo:
Review
Páginas:
373-384
PubMed:
41795054
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,998 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Chronic Disease; Europe; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; biological marker; colony stimulating factor; corticosteroid; adult; choristoma; chronic graft versus host disease; clinical trial; diagnosis; drug therapy; functional status; human; immune dysregulation; morbidity; patient-reported outcome; personalized medicine; quality of life; review; therapy; tissue repair; treatment response; adverse event; chronic disease; epidemiology; etiology; Europe; graft versus host reaction; hematopoietic stem cell transplantation; procedures

Compartir